<DOC>
	<DOCNO>NCT02694289</DOCNO>
	<brief_summary>Hypothesis : In patient , diabetes type 2 , treat metformin , admit HF , lead reduced insulin requirement , measure unit insulin , negative impact patient safety . This single center , prospective trial . Subjects randomized initiate metformin ( start dose 500mg orally daily maximum dose 2,500mg daily ) OR place insulin product management type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effects Metformin Heart Failure Patients</brief_title>
	<detailed_description>Because state insulin resistance heart failure ( HF ) , metformin , ability sensitize tissue insulin , seem ideal agent manage type 2 diabetes mellitus ( DM ) HF . It reduce concentration glucose blood enhance insulin sensitivity , induce great peripheral uptake glucose , decrease hepatic glucose output . However , accord package insert , contraindicate patient HF require pharmacologic treatment increase risk lactic acidosis . The FDA de-escalated contraindication warn evidence lack regard increase risk lactic acidosis patient type 2 DM HF take metformin . Hypothesis : In patient , diabetes type 2 , treat metformin , admit HF , metformin lead reduce insulin requirement , measure unit insulin , negative impact patient safety . Primary Objective : To test hypothesis continue patient 's home metformin diabetes management admit UK hospital result decrease utilization insulin denote total unit give . Secondary Objectives : To test hypothesis administer metformin HF patient admit UK Hospital : 1 . Results similar glycemic control ( target blood glucose &lt; 200mg/dL ) compare placebo along basis basic metabolic panel glucose value . Both group may receive conventional inpatient hyperglycemia management insulin product 2 . Reduces drug laboratory cost 3 . Reduces hospital length stay 4 . Does result hypoglycemia ( blood glucose &lt; 60 mg/dL ) 5 . Reduced discharge medication error relate diabetic medication 6 . No observed increase metabolic acidosis due elevate lactate level 7 . Does impact heart failure status ( indicated trend NT-pro BNP level ) Both diagnosis clinical management patient heart failure type 2 diabetes mellitus guarantee application standard guideline internationally recognize . All patient admit Medicine / Cardiology Advanced Heart Failure UK Hospital evaluate inclusion exclusion criterion . Based power analysis plan enroll 100 subject total . Subjects enrol January 1 , 2016 - December 31 , 2018 120 patient enrol , estimate study time frame two year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients &gt; / = 18 year age 2 . Admitted Medicine / Cardiology Advanced Heart Failure UK Hospital 3 . Carry diagnosis heart failure without preserve ejection fraction 4 . Carry diagnosis type 2 diabetes mellitus 1 . Patients &lt; 18 year age 2 . Prisoners 3 . Terminal state 4 . Known adverse reaction hypersensitivity metformin administration 5 . Pregnancy 6 . Pathological condition metformin administration clinically contraindicate ( Patients acute chronic metabolic acidosis , serum creatinine &gt; 1.4 mg/dL female , serum creatinine &gt; 1.5 mg/dL male ) 7 . Patients acute cardiovascular collapse , acute myocardial infarction , septicemia 8 . Patients carry diagnosis type 1 diabetes mellitus 9 . Patients admit diabetic ketoacidosis hyperosmotic hyperosmolar state . 10 . Patients experience diabetic ketoacidosis hyperosmotic hyperosmolar state point hospital admission . 11 . Patients admit subcutaneous insulin pump 12 . Patients , discretion Medicine / Cardiology Advanced Heart Failure service , require endocrinology consult hospitalization endocrine consult service oppose utilizing metformin particular patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>